GammaCore Approved for Treatment of Acute Migraine Pain
The use of GammaCore led to significantly higher pain-free rates for migraine attacks.
GammaCore (nVNS) has been granted 510(k) expanded clearance by the Food and Drug Administration (FDA) to treat pain associated with migraine.
GammaCore was developed by electroCore and received its initial FDA approval for the treatment of cluster headache pain in April 2017. The new approval for migraine patients was supported by the PRESTO trial, a multicenter, randomized, double-blind, sham-controlled study. A total of 243 patients with episodic migraine were included in the trial.
Results showed that use of gammaCore led to significantly higher pain-free rates than sham for the first migraine attack at 30 minutes (12.7% vs 4.2%; P =.012) and 60 minutes (21.0% vs 10.0%; P =.023). Pain-freedom at 120 minutes was also counted, and although superior to sham, it was not significantly superior (30.4% vs 19.7%; P =.067). Adverse events were low, similar to previous gammaCore studies.
"With the FDA's decision to release gammaCore for migraine, patients now have access to an effective and safe therapy which can be self-administered to acutely treat the pain associated with migraine," said Stephen D. Silberstein, MD, Professor of Neurology and Director of the Headache Center, Thomas Jefferson University.
GammaCore is a non-invasive, hand-held device which sends gentle electrical stimulation through the skin when applied to the neck. This activates the vagus nerve resulting in the reduction of pain.
The Company expects the device to be commercially available for the new indication during the second quarter of 2018. It is available through prescription only.
electroCore receives 510(k) clearance for gammaCore-S® (non-invasive vagus nerve stimulator) for the acute treatment of pain assiciated with episodic cluster headache in adult patients [press release] Basking Ridge, NJ: electroCore. Published December 14, 2017. Accessed February 1, 2018.